Genesis Therapeutics Lands Gilead Sciences Deal for AI Drug Discovery

04/10/2024

Genesis Therapeutics has secured a collaboration with Gilead Sciences, marking its third major pharma partnership. Under the agreement, Gilead will pay $35 million upfront for AI-based drug discovery on three undisclosed targets and has the option to add more targets for a set fee. Gilead gains development and commercialization rights for any resulting compounds, with Genesis eligible for milestone payments and royalties. CEO Evan Feinberg, Ph.D., highlighted that their AI platform tackles data challenges in drug discovery. Previously, Genesis partnered with Genentech and Eli Lilly and Company, and last year it raised $200 million in Series B funding from investors including Andreessen Horowitz, Fidelity Management And Research Company, BlackRock, and NVIDEA’s nVentures.

At GlenFlow, we’re excited about these advancements in AI-driven drug discovery. They inspire us as we work on more diverse applications for our ScaleFlow AI Suite. Moreover, our medical device startup, OxyDial, is led by the same fuel of constant enhancements and improving patients’ lives globally.